Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.
about
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial designDevelopment of a cell-based bioassay for phospholipase A2-triggered liposomal drug releaseMultifunctional, stimuli-sensitive nanoparticulate systems for drug deliveryDetermination of Liposomal Cisplatin by High-Performance Liquid Chromatography and Its Application in Pharmacokinetic Studies.Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.Therapeutic nanoparticles in clinics and under clinical evaluation.Strategies for triggered drug release from tumor targeted liposomes.Application of liposomal technologies for delivery of platinum analogs in oncology.Polymeric biomaterials for the delivery of platinum-based anticancer drugs.Exploiting developments in nanotechnology for the preferential delivery of platinum-based anti-cancer agents to tumours: targeting some of the hallmarks of cancer.Nanoparticle formulations of cisplatin for cancer therapy.Effect of cisplatin containing liposomes formulated by unsaturated chain-containing lipids on gynecological tumor cells.Multifunctional platinum-based nanoparticles for biomedical applications.The role of nanomaterials in translational medicineMetallomics in drug development: characterization of a liposomal cisplatin drug formulation in human plasma by CE-ICP-MS.Speciation of Phenanthriplatin and Its Analogs in the Core of Tobacco Mosaic Virus.Nanoparticles in the clinic.Liposomes Loaded with Cisplatin and Magnetic Nanoparticles: Physicochemical Characterization, Pharmacokinetics, and In-Vitro Efficacy
P2860
Q26830525-54D92C9D-2BB4-40DA-AD03-6848C02C9537Q28547031-BF90D537-ED88-453C-A20A-19787F2ED7C9Q35809872-FF9DE95C-7AFC-4D66-AEAB-8E572919C30FQ36991698-3BBD6AA9-E842-4B0D-83CE-2FEDA4B2DA7CQ37689857-D1085005-75CB-44F6-A3D0-EEC5BF899DD5Q38087986-6A8025FB-2101-43FD-8F5B-13B51A2B8F49Q38116638-BD06907D-B378-4A0B-AB51-18C86A30862EQ38136184-296914A4-3450-49DB-9526-95048F598142Q38556758-0670E6EC-505B-41F0-98E7-BF805FCC91B0Q38633157-405B9A86-FD09-48F7-8601-F4B17A446794Q38723829-7E916E57-6CEF-4DD9-A8F2-3DCF71CC30F1Q38796115-B1A45767-C82F-43A8-AE3A-DFF27D9BA82EQ38812240-2D04F3C4-19B0-4DFE-9DA2-041F60695516Q41809871-7FF973D0-06A0-452D-94D3-E19AA706ABC5Q43778320-C6145F58-61C9-4302-9A25-8E4CD4AA6E2FQ52649156-DD55330B-8234-4A7A-BE41-DE36699EE862Q55003489-08F4F74C-6EC1-48B6-9DA2-3533EF8FBDB3Q58691838-E728F133-F2F5-4793-8E6D-C499396FFAA4
P2860
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Early cessation of the clinica ...... posomal cisplatin formulation.
@ast
Early cessation of the clinica ...... posomal cisplatin formulation.
@en
type
label
Early cessation of the clinica ...... posomal cisplatin formulation.
@ast
Early cessation of the clinica ...... posomal cisplatin formulation.
@en
prefLabel
Early cessation of the clinica ...... posomal cisplatin formulation.
@ast
Early cessation of the clinica ...... posomal cisplatin formulation.
@en
P2093
P1476
Early cessation of the clinica ...... iposomal cisplatin formulation
@en
P2093
Diane van der Biessen
Hans Gelderblom
Herman Burger
Jaap Verweij
Maja J A de Jonge
Margret A G den Hollander
Marije Slingerland
Mei-Ho Lam
Ron H J Mathijssen
Walter J Loos
P304
P356
10.1016/J.EJCA.2010.07.015
P577
2010-08-26T00:00:00Z